Trending...
- Maryland Agriculture Secretary Kevin Atticks to Lead Regional Ag Association as Incoming President
- PUBLIC NOTICE Maryland Agencies to Treat Potomac River for Black Fly Control on June 27
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., ("ITI") a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid immunotherapy platform, announced today an exclusive option to license or acquire a series of innovative technologies in the immuno-oncology space from iOncologi, Inc., ("iOi").
Preclinical studies led by iOi Co-Founders, Drs. Duane Mitchell and Catherine Flores, have demonstrated that resistance to immune checkpoint inhibitors (ICIs) can be overcome by iOi's novel, intravenously delivered stem cell-based therapeutic. Rapid translation of this possible breakthrough discovery into first-in-human clinical trials is underway. ITI's option offers potential opportunities for both companies to further facilitate clinical and commercial development in the field of cell therapy and for collaboration in the development of nucleic acid vaccines that complements ITI's own UNITE™ technology. The option agreement contemplates additional investment by ITI dependent upon iOi achieving certain clinical trial milestones.
"We are pleased to expand our collaboration with Dr. Duane Mitchell, both in his role as Founder & President of iOncologi, and as a leading academic researcher in the immuno-oncology field. Dr. Mitchell has been instrumental in the development and leadership of our ATTAC-II clinical trial for patients with Glioblastoma," said Dr. William Hearl, CEO of Immunomic Therapeutics. "His determination to bring innovative treatments to patients is what compounds the complementary technologies in both companies."
More on Marylandian
"We are very excited to have iOncologi and Immunomic Therapeutics bring together complementary expertise in the advancement of new treatments for patients with refractory cancers," said Dr. Mitchell. "This agreement expands upon a longstanding and very fruitful collaboration with Dr. Hearl and the team at ITI in bringing forward novel immunotherapy treatments for patients with Glioblastoma. I look forward to the advances that will come from this agreement between the two companies."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease and allergy. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University School of Medicine. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
More on Marylandian
About iOncologi, Inc.
iOncologi, Inc. (iOi) is a privately held biotechnology company focused on the advancement of novel immunotherapies for the treatment of refractory cancers and infectious diseases. iOi's core platform technology involves the proprietary use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors (ICIs) in a variety cancers. iOi holds particular expertise in the treatment of malignant brain tumors and is focused on advancing its immunomodulatory stem cell therapy for adult and pediatric patients with malignant gliomas, as well as for patients with brain metastasis. iOi's stem cell therapy has also demonstrated a capacity to enhance the effectiveness of adoptive T cell therapy and holds significant potential in the treatment of severe infectious diseases and sepsis. iOi maintains its headquarters at The Hub at Innovation Square in Gainesville, Florida.
Contacts
iOncologi:
Barbara Frentzen
bfrentzen@ioncologi.com
352-559-5100
ITI:
Melissa Kemp
mkemp@immunomix.com
301-968-3501
Preclinical studies led by iOi Co-Founders, Drs. Duane Mitchell and Catherine Flores, have demonstrated that resistance to immune checkpoint inhibitors (ICIs) can be overcome by iOi's novel, intravenously delivered stem cell-based therapeutic. Rapid translation of this possible breakthrough discovery into first-in-human clinical trials is underway. ITI's option offers potential opportunities for both companies to further facilitate clinical and commercial development in the field of cell therapy and for collaboration in the development of nucleic acid vaccines that complements ITI's own UNITE™ technology. The option agreement contemplates additional investment by ITI dependent upon iOi achieving certain clinical trial milestones.
"We are pleased to expand our collaboration with Dr. Duane Mitchell, both in his role as Founder & President of iOncologi, and as a leading academic researcher in the immuno-oncology field. Dr. Mitchell has been instrumental in the development and leadership of our ATTAC-II clinical trial for patients with Glioblastoma," said Dr. William Hearl, CEO of Immunomic Therapeutics. "His determination to bring innovative treatments to patients is what compounds the complementary technologies in both companies."
More on Marylandian
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- YYNOT Brings High-Energy RUSH Tribute to the Weinberg Center this September
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
"We are very excited to have iOncologi and Immunomic Therapeutics bring together complementary expertise in the advancement of new treatments for patients with refractory cancers," said Dr. Mitchell. "This agreement expands upon a longstanding and very fruitful collaboration with Dr. Hearl and the team at ITI in bringing forward novel immunotherapy treatments for patients with Glioblastoma. I look forward to the advances that will come from this agreement between the two companies."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease and allergy. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University School of Medicine. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
More on Marylandian
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- PUBLIC NOTICE UPDATE: Maryland Agencies to Treat Potomac River for Black Fly Control on June 30
- Maryland: Urban Agriculture Advisory Committee Meeting Notice
About iOncologi, Inc.
iOncologi, Inc. (iOi) is a privately held biotechnology company focused on the advancement of novel immunotherapies for the treatment of refractory cancers and infectious diseases. iOi's core platform technology involves the proprietary use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors (ICIs) in a variety cancers. iOi holds particular expertise in the treatment of malignant brain tumors and is focused on advancing its immunomodulatory stem cell therapy for adult and pediatric patients with malignant gliomas, as well as for patients with brain metastasis. iOi's stem cell therapy has also demonstrated a capacity to enhance the effectiveness of adoptive T cell therapy and holds significant potential in the treatment of severe infectious diseases and sepsis. iOi maintains its headquarters at The Hub at Innovation Square in Gainesville, Florida.
Contacts
iOncologi:
Barbara Frentzen
bfrentzen@ioncologi.com
352-559-5100
ITI:
Melissa Kemp
mkemp@immunomix.com
301-968-3501
Filed Under: Business
0 Comments
Latest on Marylandian
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- INFINITI HR Expands Business Insurance Solutions: Coverage in Cyber, EPLI, Workers' Compensation
- PUBLIC NOTICE Maryland Agencies to Treat Potomac River for Black Fly Control on June 27
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- Iacocca Institute and Stanton Chase Launch Strategic Partnership for Leadership Development
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity